Cargando…

Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world

Multiple myeloma (MM) is a highly heterogeneous malignancy. The treatment of MM has been significantly advanced in recent years. B cell maturation antigen (BCMA)-targeted immunotherapy and chimeric antigen receptor T (CAR-T) cell therapy have been approved for the treatment of relapsed and refractor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Lei, Zhang, Jingyu, Punnoose, Elizabeth, Xiao, Zhenyu, Li, Wenjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262841/ https://www.ncbi.nlm.nih.gov/pubmed/37324548 http://dx.doi.org/10.1093/abt/tbad010

Ejemplares similares

Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
por: Wang, Jin, et al.
Publicado: (2022)

Consolidation in multiple myeloma – current status and perspectives
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2014)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
por: Abramson, Hanley N.
Publicado: (2023)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
por: Lonial, S, et al.
Publicado: (2016)

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions
por: Yan, Zhi-Ling, et al.
Publicado: (2022)

Insulin Injection Technique in China Compared with the Rest of the World
por: Song, Zhenqiang, et al.
Publicado: (2018)

Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions
por: Li, Pei, et al.
Publicado: (2023)

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022)

Effect of EPA on Hsp90 and GRα protein expression in multiple myeloma drug-resistant cells
por: Wu, Shenghao, et al.
Publicado: (2021)

Multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2020)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Current Main Topics in Multiple Myeloma
por: Morè, Sonia, et al.
Publicado: (2023)

Current and Emerging Treatments for Multiple Myeloma
por: Schwartz, Rowena N., et al.
Publicado: (2008)

Health‐related quality of life of patients with multiple myeloma: A real‐world study in China
por: Li, Xiaozhe, et al.
Publicado: (2020)

Comparing the prevalence of rheumatic diseases in China with the rest of the world
por: Felson, David T
Publicado: (2008)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

Current and Future PET Imaging for Multiple Myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2023)

Oral health status of patients with multiple myeloma
por: Feitosa, Édila Figuerêdo, et al.
Publicado: (2020)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
por: Tang, Wenjiao, et al.
Publicado: (2023)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
por: Jagannath, Sundar, et al.
Publicado: (2021)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Current status and trend of clinical development of orphan drugs in China
por: Xiang, Ziling, et al.
Publicado: (2022)

RENAL STATUS OF MULTIPLE MYELOMA PATIENTS IN IBADAN, NIGERIA
por: Fasola, F.A, et al.
Publicado: (2012)

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
por: Giannopoulos, K, et al.
Publicado: (2012)

Geriatrics in the Rest of the World
por: Woo, Jean
Publicado: (2010)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Adherence to immunomodulatory drugs in patients with multiple myeloma
por: Cransac, Amélie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4eu6tqnmg49k0lc6kc2odjf3al